paclitaxel has been researched along with Cardiotoxicity in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cassali, GD; da Silva, CD; de Barros, ALB; Lempek, MR; Melo, MM; Oliveira, MC; Roque, MC | 1 |
| Elshafiey, RA; Elzawawy, S; Ghoneim, A; Mostafa, TM; Werida, RH | 1 |
| Hu, W; Li, L; Song, M | 1 |
| Li, N; Liu, H; Liu, Y; Wang, M; Zhang, GQ | 1 |
| AbdulHameed Saeed, V; Mohammed, NAK | 1 |
| Beerepoot, LV; Bennink, RJ; Bijlsma, MF; Cats, A; Creemers, A; Creemers, GJ; Heisterkamp, J; Hospers, GAP; Hulshof, MCCM; Krishnadath, KK; Los, M; Mathôt, RAA; Meijer, SL; Molenaar, RJ; Nieuwenhuijzen, GAP; Punt, CJA; Schokker, S; Slingerland, M; Stroes, CI; van Berge Henegouwen, MI; van der Sangen, MJC; van der Woude, SO; van Laarhoven, HWM; van Oijen, MGH; Verhoeven, RHA | 1 |
| Dang, CT; Eaton, A; Hudis, CA; Liu, JE; Oeffinger, KC; Singh, JC; Steingart, RM; Wang, R; Yu, AF | 1 |
| Bradley, D; Colomer, R; Dang, C; Delaloge, S; Douthwaite, H; Eng-Wong, J; Ewer, MS; Ferrero, JM; Kiermaier, A; Swain, SM; Verrill, M; Viale, G; Vieira, C; Waldron-Lynch, M; Werner, TL | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Cassali, GD; de Barros, ALB; de Oliveira Silva, J; Franco, MS; Oliveira, MC; Roque, MC | 1 |
| Andrés, R; Calvo, I; Canes, J; Ciruelos, E; Gavilá, J; Gonzàlez, X; Llombart-Cussac, A; Marín-Aguilera, M; Martínez, D; Martínez, J; Morales, S; Muñoz, M; Oliveira, M; Paré, L; Pascual, T; Perelló, A; Perez-Garcia, J; Prat, A; Quero, JC; Ruiz, I; Virizuela, JA | 1 |
| Braunstein, LZ; Cahlon, O; Dang, CT; Eaton, A; Ho, AY; Lee Chuy, K; Liu, JE; Mara, E; Oeffinger, KC; Steingart, RM; Thor, ME; Yu, AF | 1 |
| Jyoti, S; Tandon, S | 1 |
| Baselga, J; Bellet, M; Blasco, C; Garcia-Martínez, E; Gil-Gil, MJ; Llombart, A; Manso, L; Martinez-Jáñez, N; Melé, M; Mesia, C; Morales, S; Ojeda, B; Pernas, S; Villagrasa, P | 1 |
| Dang, CT; Fleisher, M; Hudis, CA; Jones, LW; Liu, JE; Manrique, C; Mara, E; Patil, S; Pun, S; Steingart, RM; Yu, AF | 1 |
| Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E | 1 |
| Sohn, JT | 1 |
| Alarfaj, M; Goswami, A | 1 |
| Conil, JM; Delmas, C; Gallart, JC; Ruiz, S; Tardif, E; Vardon Bounes, F | 1 |
1 review(s) available for paclitaxel and Cardiotoxicity
| Article | Year |
|---|---|
Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Death; Female; Heart Failure; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2022 |
8 trial(s) available for paclitaxel and Cardiotoxicity
| Article | Year |
|---|---|
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Doxorubicin; Female; Humans; Neurotensin; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Thioctic Acid; Tumor Necrosis Factor-alpha | 2022 |
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cardiotoxicity; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Male; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2020 |
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Chemotherapy, Adjuvant; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polyethylene Glycols; Receptor, ErbB-2; Trastuzumab | 2019 |
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxicity; Comorbidity; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Risk Factors; Treatment Outcome | 2015 |
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Female; Humans; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin I; Ventricular Function, Left | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cisplatin; Cyclophosphamide; Diarrhea; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab | 2016 |
10 other study(ies) available for paclitaxel and Cardiotoxicity
| Article | Year |
|---|---|
Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio.
Topics: Action Potentials; Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Doxorubicin; Drug Compounding; Drug Synergism; Electrocardiography; Female; Heart Diseases; Lethal Dose 50; Lipids; Liposomes; Mice, Inbred BALB C; Myocytes, Cardiac; Paclitaxel | 2021 |
[Ginsenoside Rg_3 based liposomes target delivery of dihydroartemisinin and paclitaxel for treatment of triple-negative breast cancer].
Topics: Cardiotoxicity; Cell Line, Tumor; Ginsenosides; Humans; Liposomes; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Biosimilar Pharmaceuticals; Breast Neoplasms; Cardiotoxicity; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cardiotoxicity; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Humans; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Paclitaxel; Random Allocation; Tumor Burden | 2019 |
Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Echocardiography, Doppler; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Trastuzumab; Ventricular Dysfunction, Left | 2019 |
Disruption of mitochondrial membrane potential coupled with alterations in cardiac biomarker expression as early cardiotoxic signatures in human ES cell-derived cardiac cells.
Topics: Biomarkers; Cardiotoxicity; Cell Line; Cell Survival; Doxorubicin; Homeobox Protein Nkx-2.5; Humans; Membrane Potential, Mitochondrial; Myocytes, Cardiac; Myosin Heavy Chains; Paclitaxel; Penicillin G; T-Box Domain Proteins | 2019 |
Putative Mechanisms Associated With Lipid Emulsion Treatment for Cardiac Toxicity Caused by Yew Intoxication.
Topics: Cardiotoxicity; Emulsions; Fat Emulsions, Intravenous; Humans; Lipids; Plant Poisoning; Taxus | 2022 |
Cardiotoxicity in yew berry poisoning.
Topics: Arrhythmias, Cardiac; Cardiotoxicity; Fatal Outcome; Female; Fruit; Humans; Shock, Cardiogenic; Suicide; Taxus; Young Adult | 2021 |
Suicide attempt with self-made Taxus baccata leaf capsules: survival following the application of extracorporeal membrane oxygenation for ventricular arrythmia and refractory cardiogenic shock.
Topics: Administration, Oral; Adult; Capsules; Cardiotoxicity; Chromatography, High Pressure Liquid; Electrocardiography; Extracorporeal Membrane Oxygenation; Humans; Male; Metabolic Clearance Rate; Plant Extracts; Plant Leaves; Plant Poisoning; Renal Replacement Therapy; Shock, Cardiogenic; Suicide, Attempted; Tachycardia, Ventricular; Tandem Mass Spectrometry; Taxus; Treatment Outcome | 2017 |